Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
For AFib patients with a history of brain bleeds, starting blood thinners may do more good than harm. A Finnish study found that direct oral anticoagulants (DOACs) significantly cut the risk of ischemic stroke and death — without meaningfully raising the risk of another brain bleed. Warfarin also helped, but came with a higher rebleeding risk.
Prescribing blood thinners to atrial fibrillation (AFib) patients who've had a prior brain bleed has long been a difficult clinical decision — but new data suggests the benefits may outweigh the risks for many patients. A nationwide Finnish cohort study tracked 1,502 adults with AFib and a history of intracranial bleeding, comparing outcomes across those on DOACs, warfarin, or no anticoagulation over two years.
The results were notable: DOAC users saw significantly lower rates of ischemic stroke and death compared to those on no anticoagulation, with no statistically significant increase in brain bleed recurrence. Warfarin also reduced stroke and death risk, but was tied to a nearly doubled risk of rebleeding — especially in patients with poor INR control.
By the Numbers:
Why it matters: This study gives clinicians meaningful real-world data to support individualized anticoagulation decisions in one of cardiology and neurology's most challenging patient populations. DOACs appear to offer the best risk-benefit profile, while warfarin's safety hinges heavily on tight INR management.
